Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, doctors can increasingly tailor Alzheimer’s drugs based on disease stage, and this approach is transforming how the disease is treated. With the FDA approval of new disease-modifying drugs like lecanemab and donanemab specifically designed for early-stage disease, combined with advances in blood-based biomarkers that can pinpoint disease progression, clinicians now have concrete tools to match treatments to where a patient actually is in their disease journey. A 72-year-old woman experiencing mild cognitive decline might benefit from lecanemab’s ability to slow cognitive decline by 27 percent, while someone in a later stage would likely continue with traditional symptomatic treatments that have proven safer profiles for moderate and advanced disease. The shift toward stage-matched treatment represents a fundamental change from the one-size-fits-all approach of the past.
Rather than waiting for cognitive symptoms to become obvious, doctors can now use plasma biomarkers—measurable proteins in blood that reflect brain pathology—to identify who has early Alzheimer’s pathology and might benefit from newer drugs. These biomarkers like phosphorylated tau-217 and tau-231 can detect Alzheimer’s changes years before symptoms appear, enabling much earlier intervention when drugs like lecanemab show their greatest benefit. This doesn’t mean every Alzheimer’s patient is now a candidate for every new drug. Stage-specific efficacy remains crucial: drugs approved for early-stage disease show the strongest evidence in mild cognitive impairment or mild dementia, not in moderate or severe stages. Treatment decisions still require careful assessment of individual risk factors, access to required monitoring, and cost considerations that can reach thousands of dollars annually.
Table of Contents
- Can We Identify Alzheimer’s Stage with Blood Tests Rather Than Brain Imaging?
- What Drug Choices Actually Exist for Different Alzheimer’s Stages?
- How Do Emerging Tau-Targeting Drugs Change Stage-Specific Treatment?
- What Are the Real Costs and Coverage Barriers for Stage-Matched Treatment?
- What Are the Safety and Side Effect Challenges of Stage-Matched Drugs?
- How Does Biological Staging Differ from Clinical Staging?
- What Does Stage-Matched Alzheimer’s Treatment Look Like in Five Years?
- Conclusion
Can We Identify Alzheimer’s Stage with Blood Tests Rather Than Brain Imaging?
Blood-based biomarkers have emerged as a game-changer for identifying disease stage without expensive and time-consuming brain imaging. Plasma phosphorylated tau—specifically p-tau217 and p-tau231—shows remarkable accuracy in detecting both amyloid accumulation and early tau pathology, the two hallmark changes in Alzheimer’s brains. Research has demonstrated that these blood markers maintain strong consistency across different patient populations and correlate closely with clinical diagnoses and disease stage determined by PET imaging, making them potentially accessible tools for broader populations. The practical advantage is substantial: a standard blood test can now reveal whether someone has preclinical Alzheimer’s pathology or early cognitive decline attributable to Alzheimer’s changes, allowing physicians to consider disease-modifying drugs much earlier.
This is particularly important because the newest drugs like lecanemab show their greatest benefit when given in these earliest stages. However, blood tests alone don’t replace clinical evaluation—they must be interpreted alongside cognitive assessments and clinical judgment. A positive biomarker combined with cognitive symptoms provides much stronger evidence for stage-specific treatment than biomarkers alone. The sequential dynamics of these biomarkers reveal another staging insight: plasma p-tau217 rises markedly before other tau measurements, suggesting it could help identify the very earliest disease stages where intervention might be most effective. This biological sequencing means doctors might eventually use different biomarker thresholds to determine not just whether someone has Alzheimer’s, but which stage they’re in and therefore which treatments make most sense.
What Drug Choices Actually Exist for Different Alzheimer’s Stages?
The medication landscape for Alzheimer’s divides clearly between early-stage disease-modifying drugs and standard treatments for all stages. For early-stage Alzheimer’s disease (mild cognitive impairment and mild dementia), two FDA-approved monoclonal antibodies now offer disease modification: lecanemab, approved in July 2023, showed a 27 percent reduction in cognitive and functional decline over 18 months compared to placebo, with separate data showing a 26 percent slowing of cognitive decline and a 37 percent slowing of decline in daily living activities. Donanemab, FDA approved in July 2024, demonstrated 24 to 35 percent slowing of disease progression in clinical trials involving over 1,700 participants. Yet these early-stage drugs are not interchangeable, and neither is appropriate for moderate to severe dementia. For patients in mild, moderate, or severe stages, standard symptomatic treatments—cholinesterase inhibitors and memantine—remain the evidence-based option. These drugs don’t slow disease progression but improve or stabilize cognitive function and behavior for many patients.
A person with moderate Alzheimer’s considering treatment would typically continue or start these medications, not switch to the newer monoclonal antibodies that showed no benefit in advanced disease stages. The fundamental limitation of newer drugs is their stage specificity: efficacy evidence supports their use only in early disease, and using them in moderate or severe stages risks cost and potential harms without demonstrated benefit. Recent updates have improved treatment options within the early-stage category. In 2026, the FDA approved a new maintenance dosing regimen for lecanemab that extends from biweekly to once every four weeks after the initial 18 months of treatment, potentially reducing infusion burden. The same year, the FDA approved a subcutaneous autoinjector formulation of lecanemab that achieved 14 percent greater amyloid plaque clearance compared with intravenous dosing after six months. This means early-stage patients now have choices about how to receive their treatment—weekly intravenous infusions during the initial phase, less frequent maintenance infusions, or eventually subcutaneous injection—allowing individualization based on lifestyle and preferences.
How Do Emerging Tau-Targeting Drugs Change Stage-Specific Treatment?
Beyond anti-amyloid drugs, tau-targeting therapies are entering clinical trials and may further expand stage-matched treatment options. In May 2026, Biogen announced Phase 2 results for diranersen, an investigational tau-targeting drug, showing reductions in tau and signals of slowed cognitive decline. Multiple Phase 3 combination trials are now underway testing whether drugs targeting tau pathology, when combined with anti-amyloid treatments, might offer additive benefit. These combinations include monoclonal antibodies targeting both tau and amyloid-beta, gamma secretase modulators combined with anti-amyloid antibodies, and tau vaccines combined with anti-amyloid treatments. Research has identified 17 different aspects of Alzheimer’s brain damage now targeted by at least one drug in current clinical trials, suggesting that future stage-matched treatment may become more complex and individualized.
Rather than a single drug for early-stage disease, a physician might choose a combination tailored to which pathological processes are most prominent in that patient’s brain. The challenge will be determining which combinations work best, whether they’re safe together, and how to sequence them for maximum benefit—questions that will take years of rigorous trials to answer. For now, these combination approaches remain investigational, and doctors should not expect them to become standard treatment options immediately. The evidence supporting combination therapy in Alzheimer’s is not yet as robust as the single-drug evidence for lecanemab and donanemab. Any patient considering newer combination treatments should be doing so only within the context of a clinical trial with clear understanding of the experimental nature and potential risks.
What Are the Real Costs and Coverage Barriers for Stage-Matched Treatment?
Cost represents a major practical barrier to stage-matched Alzheimer’s treatment. Lecanemab costs approximately $26,500 annually, while donanemab carries costs of about $12,522 for six months, or up to $48,896 for an 18-month treatment course—approximately $32,000 annually. Beyond the drug cost itself, treatment requires hundreds to thousands of dollars in necessary brain imaging (MRI or PET) and monitoring appointments. For an uninsured person or someone with high deductible insurance, these costs can be prohibitive regardless of how perfectly their disease stage matches the drug indication. Medicare coverage exists for both lecanemab and Kisunla (donanemab) as of 2026, but specific enrollment and monitoring requirements apply.
Coverage is conditional on documented cognitive impairment and confirmed amyloid pathology, typically requiring PET imaging or blood biomarker confirmation. The practical effect is that while Medicare beneficiaries have coverage, they may still face copays, deductibles, and the burden of proving amyloid pathology through imaging. Private insurance coverage varies considerably, with some plans fully covering these drugs while others require prior authorization or deny coverage entirely. A 65-year-old with early Alzheimer’s and Medicare coverage might afford treatment, while a 62-year-old with early-stage disease and private insurance might find coverage denied until they’re Medicare-eligible—a cruel irony given that evidence suggests younger patients might benefit most from early intervention. The staging approach creates a troubling equity concern: the patients most likely to benefit from lecanemab and donanemab are those identified early through screening, who then need expensive biomarker testing and brain imaging to confirm diagnosis. Socioeconomically disadvantaged populations may have less access to cognitive screening, specialist care, and the blood tests and imaging needed to diagnose early-stage disease, meaning they’re less likely to be identified as candidates for stage-matched treatment even if it’s covered.
What Are the Safety and Side Effect Challenges of Stage-Matched Drugs?
The newest Alzheimer’s drugs, while disease-modifying, carry significant risks that make their stage-specific use even more important. Both lecanemab and donanemab carry a black box warning for amyloid-related imaging abnormalities (ARIA)—brain changes visible on MRI that can include microhemorrhages, micro-infarcts, and brain swelling. ARIA appears more frequently in people carrying the APOE4 genetic risk variant, and serious cases can cause cognitive worsening, seizures, or permanent brain damage. These severe complications remain rare, but they’re serious enough that they practically require regular MRI monitoring—adding to costs and burden. This safety profile explains why these drugs are restricted to early-stage disease: in someone with mild cognitive impairment, the potential 27-percent slowing of decline might outweigh the ARIA risk.
In someone with severe dementia already experiencing significant cognitive loss, adding ARIA risk on top of existing brain damage makes little sense. The stage-specific approval is therefore not just about efficacy but about risk-benefit calculations that shift as disease progresses. A patient starting lecanemab in early stage must commit to regular brain imaging, risk acceptance conversations, and careful monitoring—not all patients are comfortable with this approach even if their disease stage technically qualifies them. Additionally, the required amyloid pathology for these drugs means they’re useful only for Alzheimer’s disease driven by amyloid and tau, not for other forms of dementia. Someone diagnosed with early cognitive decline from vascular dementia, Lewy body disease, or frontotemporal dementia would not benefit from lecanemab despite potentially having early-stage disease, because these drugs target amyloid pathology not present in those conditions. The stage-matching approach therefore requires accurate diagnosis first—another practical challenge for primary care physicians who may lack access to specialized diagnostic testing.
How Does Biological Disease Stage Differ from Clinical Staging?
Traditional Alzheimer’s staging relies on clinical symptoms: cognitive impairment severity, functional decline, and behavioral changes. Biological staging—using plasma biomarkers and imaging to detect pathological changes—is increasingly revealing that biological disease can precede clinical symptoms by years or even decades. A patient might show positive amyloid and tau biomarkers, qualifying them as biologically stage 1 or 2, while still performing normally on cognitive testing and denying any memory complaints. This person is biologically “staged” as having early disease but clinically appears healthy.
This distinction matters for treatment decisions. Lecanemab and donanemab carry clearest evidence in people with both biomarker evidence of amyloid and tau plus mild cognitive impairment—biological and clinical staging aligned. A person with only preclinical amyloid pathology but no cognitive impairment would not be a standard candidate for these drugs, though researchers are investigating whether treating in the purely preclinical stage might prevent cognitive decline from ever developing. These preclinical treatment trials, if successful, would further shift Alzheimer’s treatment backward toward presymptomatic disease identification and prevention, making the stage-matching question even more relevant.
What Does Stage-Matched Alzheimer’s Treatment Look Like in Five Years?
The trajectory of Alzheimer’s treatment strongly suggests that stage-matched approaches will become increasingly precise and individualized. As more tau-targeting drugs advance through trials and potentially gain approval, physicians will likely choose among multiple options based on which pathological process—amyloid accumulation, tau tangles, or both—predominates in an individual patient’s brain. Blood biomarkers will likely become routine screening tools in primary care, allowing earlier identification of people in preclinical stages of disease. More treatment combinations will be tested, potentially allowing tailored cocktails designed specifically for an individual’s biological stage and pathological profile.
The practical implication is that Alzheimer’s treatment in 2030 or 2031 may look quite different from today. Earlier identification will lead to earlier treatment initiation. More precise biomarkers may allow distinction between not just early and late disease, but specific subtypes of early disease with different treatment responses. What remains uncertain is whether these advances will become accessible to all patients or whether they’ll remain available primarily to those with resources for specialist care, genetic testing, and imaging. Doctors today are already tailoring Alzheimer’s drugs by disease stage; the question for the coming years is whether that tailoring will become standard of care across all healthcare systems or remain concentrated in specialty centers with wealth and expertise.
Conclusion
Doctors can now tailor Alzheimer’s drugs based on disease stage in ways that weren’t possible just a few years ago. The approval of lecanemab and donanemab for early-stage disease, combined with blood-based biomarkers that can identify disease stage without expensive imaging, has created a new treatment paradigm where earlier identification enables earlier intervention with drugs that actually slow disease progression. The stage-matched approach recognizes that efficacy, safety, and cost-effectiveness all vary dramatically depending on where someone is in their disease journey, making treatment individualization not just better practice but essential practice.
If you or a loved one is experiencing cognitive changes or memory concerns, the first step is a discussion with your primary care physician about whether cognitive screening and biomarker testing might be appropriate. Specialist evaluation by a neurologist or memory disorder clinic can determine disease stage with greater precision and help clarify whether stage-matched treatment options like lecanemab or donanemab might be candidates for consideration. Understanding your disease stage is increasingly the foundation of effective Alzheimer’s treatment planning.
You Might Also Like
- Could New Alzheimer’s Drugs Help People Beyond Early Stages?
- Why Researchers Are Linking Alzheimer’s and Parkinson’s Diagnostics
- What Shared Biomarkers Mean for Alzheimer’s and Parkinson’s
Related reading
- how Families Should Prepare for Alzheimer’s Test Results
- why Test Accuracy Matters in Dementia Diagnosis
- can False Positives Harm Alzheimer’s Patients
- what Alzheimer’s Blood Tests Cannot Tell You Yet
- why Dementia Diagnosis Still Needs Clinical Evaluation
For more on this topic, see NIH MedlinePlus — dementia.
